Premium
Mechanistic/mammalian target of rapamycin: Recent pathological aspects and inhibitors
Author(s) -
AbdelMaksoud Mohammed S.,
ElGamal Mohammed I.,
Benhalilou Dalia Reyane,
Ashraf Sandy,
Mohammed Shatha Abdulghaffar,
Oh ChangHyun
Publication year - 2019
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21535
Subject(s) - pi3k/akt/mtor pathway , autophagy , mechanistic target of rapamycin , kinase , cell growth , biology , rptor , discovery and development of mtor inhibitors , mtorc2 , transcription (linguistics) , adenosine triphosphate , cancer research , microbiology and biotechnology , chemistry , mtorc1 , signal transduction , biochemistry , apoptosis , linguistics , philosophy
The mechanistic/mammalian target of rapamycin (mTOR), also known as the mechanistic target of rapamycin, regulates many normal cell processes such as transcription, cell growth, and autophagy. Overstimulation of mTOR by its ligands, amino acids, sugars, and/or growth factors leads to physiological disorders, including cancer and neurodegenerative diseases. In this study, we reviewed the recent advances regarding the mechanism that involves mTOR in cancer, aging, and neurodegenerative diseases. The chemical and biological properties of recently reported small molecules that function as mTOR kinase inhibitors, including adenosine triphosphate‐competitive inhibitors and dual mTOR/PI3K inhibitors, have also been reviewed. We focused on the reports published in the literature from 2012 to 2017.